Compare CRDF & PEW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CRDF | PEW |
|---|---|---|
| Founded | 1999 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Other Specialty Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.1M | 56.7M |
| IPO Year | 2012 | 2025 |
| Metric | CRDF | PEW |
|---|---|---|
| Price | $0.87 | $1.31 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.14 | N/A |
| AVG Volume (30 Days) | ★ 1.0M | 496.3K |
| Earning Date | 11-12-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 27.37 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $365,993.00 | ★ $96,449,000.00 |
| Revenue This Year | N/A | $3.99 |
| Revenue Next Year | N/A | $6.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 49.61 | 3.57 |
| 52 Week Low | $0.71 | $1.28 |
| 52 Week High | $3.31 | $3.84 |
| Indicator | CRDF | PEW |
|---|---|---|
| Relative Strength Index (RSI) | N/A | N/A |
| Support Level | N/A | N/A |
| Resistance Level | N/A | N/A |
| Average True Range (ATR) | 0.00 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 0.00 |
Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.
GrabAGun Digital Holdings Inc is a multi-brand eCommerce retailer of firearms, ammunition and related accessories. The Company's firearm products are ordered and paid for by customers online through the Company's eCommerce site and mobile app and are delivered to them on-premises through their choice of federal firearm licensed dealers nationwide. The Company's network of localized firearm dealers perform background checks on firearms purchasers and complete sales forms as mandated by federal and state firearm regulations.